Vertex Pharmaceuticals Inc. director Daniel J. Brennan acquired 795 shares of common stock directly through a restricted stock unit award on October 20, 2026, with a reported price of $503.47 per share. His reported direct holdings after the award were 795 shares. The award vests, subject to certain limited exceptions, on the first anniversary of the grant date.
Vertex Pharmaceuticals Incorporated appointed Daniel Brennan to its board of directors on October 20, 2026, increasing the board from ten to eleven members. Brennan also joined the Audit and Finance Committee. Upon joining, he received a $400,000 restricted stock unit award that will vest in October 2027.
Brennan served as executive vice president and chief financial officer of Boston Scientific Corporation from January 2014 until his retirement in June 2025. He has served on the boards of Waters Corporation since November 2022 and Madrigal Pharmaceuticals since August 2025. Vertex stated there are no transactions with Brennan requiring disclosure and no arrangement or understanding with another person pursuant to which he was appointed.
Vertex Pharmaceuticals Inc. director Bruce I. Sachs acquired 92.694 deferred stock units on October 15, 2026. Each unit represents one share of common stock, and his reported post-transaction holding was 15,864.501 units. The units are paid out in common stock upon the earliest of termination of his board service, a change of control, disability or death.
Vertex Pharmaceuticals Inc. director Alan M. Garber received an award of 29.2720 deferred stock units on October 15, 2026. Each unit represents one share of common stock and is paid in common stock upon the earliest of Dr. Garber’s board-service termination, a change of control, disability or death. His reported position after the award was 94.7300 deferred stock units.
VERTEX PHARMACEUTICALS INC / MA (symbol: VRTX) is the issuer of record for a Form 4 filing submitted to the SEC. van Grunsven Jasper reported acquisition or exercise transactions in this Form 4 filing.
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported that executive vice president Jasper van Grunsven received an award of 8,682 shares of common stock on September 8, 2026, as a stock-based compensation grant at no cash purchase price.
The award is in the form of restricted stock units that vest in installments beginning on September 8, 2027. After this grant, he is reported as directly holding 8,682 common shares. No transactions were reported under a Rule 10b5-1 trading plan.
VERTEX PHARMACEUTICALS INC / MA (VRTX) filed an initial statement of beneficial ownership for Jasper van Grunsven, who serves as EVP, CP and NPPO. The Form 3 lists no reportable holdings or transactions in Vertex securities at the time of this filing. A Power of Attorney is noted as Exhibit 24.
VERTEX PHARMACEUTICALS INC / MA (symbol: VRTX) is the issuer of record for a Form 4 filing submitted to the SEC.
VERTEX PHARMACEUTICALS INC / MA (VRTX) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer, effective January 1, 2027, while Charles F. Wagner, Jr. will remain Executive Vice President and Chief Operating Officer. Poole has served as Senior Vice President, Finance at Vertex since March 2020 and previously held CFO roles at several biotechnology companies.
Under his new employment agreement, Poole will receive a $750,000 base salary and a target annual bonus of 90% of base salary. If terminated without cause or he resigns for good reason, he is entitled to cash severance equal to 100% of base salary and target bonus, plus any earned but unpaid prior-year bonus, subject to a release. A separate change of control agreement provides for similar cash benefits, a pro‑rated target bonus, payment of other earned incentives, and full vesting of outstanding equity awards upon qualifying terminations around a change of control, plus up to 12 months of Company-paid medical, dental, and life insurance premiums if COBRA coverage is elected.
VERTEX PHARMACEUTICALS INC / MA (VRTX) director Bruce I. Sachs reported a disposition of common stock through a bona fide gift. On 2026-08-27, he transferred 6,000 shares of Vertex common stock, recorded at $0.00 per share for reporting purposes, and reported holding 39,000 shares directly afterward.